Video
Dr. Nickel discusses promising outcomes with vaccine for recurrent UTIs
Author(s):
“We were able to show that there was a very…clinically significant decrease in the rate of UTIs in the vaccinated group, preventing UTIs in almost 60% of vaccinated patients,” says J. Curtis Nickel, MD.
Video Player is loading.
In this video, J. Curtis Nickel, MD, discusses the findings and further research associated with the study, “A novel sublingual vaccine will dramatically alter the clinical management of recurrent urinary tract infections in women,” presented at the 2021 American Urological Association Annual Meeting. Nickel is a professor of the department of urology at Queen’s University and urologist at Kingston and Hotel Dieu General Hospitals, Kingston, Ontario, Canada.
Related Videos
5 key trial insights from AUA 2025
Félix Guerrero-Ramos, MD, on TAR-200 in papillary disease-only NMIBC
Khurshid Ghani, MD, on trial of stent omission following ureteroscopy
Shreyas Joshi, MD, recaps AUA session on chemotherapy vs novel NMIBC options
Shay Rajavel, MS3, on CO2 gas embolism during single-port partial nephrectomy
Kevin Zorn, MD, on preserving ejaculation with BPH therapies
Neal Shore, MD, on sasanlimab plus BCG for BCG-naïve NMIBC
Alexander Glaser, MD, on real-world outcomes with Aquablation
Vitaly Margulis, MD, on preliminary safety, efficacy of padeliporfin VTP for UTUC
Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
Related Content
